Literature DB >> 22009150

Structural basis for activation and inhibition of class I phosphoinositide 3-kinases.

Oscar Vadas1, John E Burke, Xuxiao Zhang, Alex Berndt, Roger L Williams.   

Abstract

Phosphoinositide 3-kinases (PI3Ks) are implicated in a broad spectrum of cellular activities, such as growth, proliferation, differentiation, migration, and metabolism. Activation of class I PI3Ks by mutation or overexpression correlates with the development and maintenance of various human cancers. These PI3Ks are heterodimers, and the activity of the catalytic subunits is tightly controlled by the associated regulatory subunits. Although the same p85 regulatory subunits associate with all class IA PI3Ks, the functional outcome depends on the isotype of the catalytic subunit. New PI3K partners that affect the signaling by the PI3K heterodimers have been uncovered, including phosphate and tensin homolog (PTEN), cyclic adenosine monophosphate-dependent protein kinase (PKA), and nonstructural protein 1. Interactions with PI3K regulators modulate the intrinsic membrane affinity and either the rate of phosphoryl transfer or product release. Crystal structures for the class I and class III PI3Ks in complexes with associated regulators and inhibitors have contributed to developing isoform-specific inhibitors and have shed light on the numerous regulatory mechanisms controlling PI3K activation and inhibition.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22009150     DOI: 10.1126/scisignal.2002165

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  97 in total

1.  The structural basis for Ras activation of PI3Kα lipid kinase.

Authors:  Mingzhen Zhang; Hyunbum Jang; Ruth Nussinov
Journal:  Phys Chem Chem Phys       Date:  2019-06-05       Impact factor: 3.676

Review 2.  Toll-like receptors, signaling adapters and regulation of the pro-inflammatory response by PI3K.

Authors:  Ty Dale Troutman; J Fernando Bazan; Chandrashekhar Pasare
Journal:  Cell Cycle       Date:  2012-08-16       Impact factor: 4.534

Review 3.  Targeting the protein-protein interaction between IRS1 and mutant p110α for cancer therapy.

Authors:  Yujun Hao; Shuliang Zhao; Zhenghe Wang
Journal:  Toxicol Pathol       Date:  2013-10-31       Impact factor: 1.902

Review 4.  Interplay between phosphoinositide lipids and calcium signals at the leading edge of chemotaxing ameboid cells.

Authors:  Joseph J Falke; Brian P Ziemba
Journal:  Chem Phys Lipids       Date:  2014-01-19       Impact factor: 3.329

Review 5.  Crossroads of PI3K and Rac pathways.

Authors:  Carlo C Campa; Elisa Ciraolo; Alessandra Ghigo; Giulia Germena; Emilio Hirsch
Journal:  Small GTPases       Date:  2015-05-05

Review 6.  The biology behind PI3K inhibition in chronic lymphocytic leukaemia.

Authors:  Valentín Ortiz-Maldonado; Marcial García-Morillo; Julio Delgado
Journal:  Ther Adv Hematol       Date:  2015-02

Review 7.  Dynamic structural biology at the protein membrane interface.

Authors:  John E Burke
Journal:  J Biol Chem       Date:  2019-01-28       Impact factor: 5.157

Review 8.  PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances.

Authors:  Lomon So; David A Fruman
Journal:  Biochem J       Date:  2012-03-15       Impact factor: 3.857

9.  Targeting PI3K in Cancer: Any Good News?

Authors:  Miriam Martini; Elisa Ciraolo; Federico Gulluni; Emilio Hirsch
Journal:  Front Oncol       Date:  2013-05-08       Impact factor: 6.244

10.  Molecular mechanism of activation of class IA phosphoinositide 3-kinases (PI3Ks) by membrane-localized HRas.

Authors:  Braden D Siempelkamp; Manoj K Rathinaswamy; Meredith L Jenkins; John E Burke
Journal:  J Biol Chem       Date:  2017-05-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.